Report overview
Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called ?Insulin glargine? and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first ?biosimilar? insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.
This report aims to provide a comprehensive presentation of the global market for Biosimilars Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars Insulin. This report contains market size and forecasts of Biosimilars Insulin in global, including the following market information:
Global Biosimilars Insulin Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Biosimilars Insulin Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Biosimilars Insulin companies in 2022 (%)
The global Biosimilars Insulin market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi?s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.
We surveyed the Biosimilars Insulin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biosimilars Insulin Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biosimilars Insulin Market Segment Percentages, by Type, 2022 (%)
Insulin Glargine
Insulin Aspart
Insulin Lispro
Other
Global Biosimilars Insulin Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biosimilars Insulin Market Segment Percentages, by Application, 2022 (%)
Type I Diabetes
Type II Diabetes
Global Biosimilars Insulin Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biosimilars Insulin Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biosimilars Insulin revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Biosimilars Insulin revenues share in global market, 2022 (%)
Key companies Biosimilars Insulin sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Biosimilars Insulin sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
Boehringer Ingelheim
Biocon/Mylan
Gan & Lee Pharmaceuticals
Tonghua Dongbao
United Laboratories
Sanofi
Outline of Major Chapters:
Chapter 1: Introduces the definition of Biosimilars Insulin, market overview.
Chapter 2: Global Biosimilars Insulin market size in revenue and volume.
Chapter 3: Detailed analysis of Biosimilars Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biosimilars Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Biosimilars Insulin capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
